Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 09 04:00PM ET
0.6106
Dollar change
+0.0456
Percentage change
8.07
%
Index- P/E- EPS (ttm)-4.56 Insider Own2.53% Shs Outstand5.09M Perf Week-2.29%
Market Cap3.13M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float4.96M Perf Month10.02%
Income-21.13M PEG- EPS next Q-0.78 Inst Own26.17% Short Float1.88% Perf Quarter-83.04%
Sales0.00M P/S- EPS this Y26.18% Inst Trans69.05% Short Ratio0.45 Perf Half Y-92.41%
Book/sh3.10 P/B0.20 EPS next Y63.05% ROA-83.91% Short Interest0.09M Perf Year-94.47%
Cash/sh2.12 P/C0.29 EPS next 5Y- ROE-108.57% 52W Range0.50 - 21.50 Perf YTD-94.35%
Dividend Est.- P/FCF- EPS past 5Y7.12% ROI-116.67% 52W High-97.16% Beta1.59
Dividend TTM- Quick Ratio5.53 Sales past 5Y1874.16% Gross Margin- 52W Low22.12% ATR (14)0.14
Dividend Ex-Date- Current Ratio5.53 EPS Y/Y TTM6.87% Oper. Margin- RSI (14)30.81 Volatility9.59% 18.01%
Employees32 Debt/Eq0.19 Sales Y/Y TTM-100.00% Profit Margin- Recom2.00 Target Price30.00
Option/ShortNo / Yes LT Debt/Eq0.15 EPS Q/Q39.10% Payout- Rel Volume0.40 Prev Close0.56
Sales Surprise- EPS Surprise19.43% Sales Q/Q- EarningsNov 06 Avg Volume209.08K Price0.61
SMA20-2.62% SMA50-67.04% SMA200-91.34% Trades Volume83,836 Change8.07%
Date Action Analyst Rating Change Price Target Change
May-11-21Downgrade Piper Sandler Overweight → Neutral
Aug-26-20Resumed Piper Sandler Overweight
Jan-27-20Initiated Piper Sandler Overweight $3
Jan-24-20Initiated SunTrust Buy
Jan-23-20Initiated SunTrust Buy
Jan-09-20Initiated Aegis Capital Buy $3.50
Jun-26-19Initiated H.C. Wainwright Buy $4
Oct-31-24 06:30AM
Oct-25-24 01:01PM
Sep-02-24 09:21AM
Aug-14-24 04:05PM
Aug-07-24 07:00AM
08:30AM Loading…
Jun-24-24 08:30AM
Jun-13-24 07:00AM
May-16-24 07:00AM
May-10-24 01:22PM
12:46PM
May-09-24 04:05PM
May-07-24 08:00AM
May-02-24 07:00AM
Apr-30-24 08:00AM
Apr-03-24 08:30AM
02:24PM Loading…
Apr-01-24 02:24PM
Mar-28-24 06:46AM
Mar-27-24 04:05PM
Mar-25-24 08:00AM
Mar-22-24 12:37PM
09:15AM
06:30AM
Feb-26-24 08:00AM
Feb-20-24 07:30AM
Jan-03-24 07:00AM
Dec-27-23 07:30AM
Dec-21-23 07:30AM
Nov-10-23 01:15PM
Nov-09-23 08:52AM
08:41AM
06:42PM Loading…
Nov-08-23 06:42PM
04:05PM
Nov-07-23 07:30AM
Nov-01-23 07:00AM
Oct-11-23 07:30AM
Sep-28-23 07:00AM
Sep-27-23 07:00AM
Sep-22-23 05:25PM
Sep-21-23 09:35AM
Sep-06-23 07:00AM
Aug-22-23 07:30AM
Aug-10-23 11:05AM
Aug-09-23 04:05PM
Aug-02-23 07:00AM
Jul-26-23 08:00AM
May-11-23 01:44PM
07:30AM
06:30AM
May-10-23 05:15PM
04:05PM
May-03-23 07:00AM
May-02-23 02:16PM
Apr-27-23 06:36PM
Apr-18-23 08:00AM
Mar-18-23 03:12AM
Mar-16-23 05:42AM
Mar-15-23 04:05PM
Mar-08-23 07:00AM
Mar-02-23 07:00AM
Jan-30-23 04:01PM
Jan-23-23 07:00AM
Jan-20-23 10:49AM
Jan-12-23 07:00AM
Nov-02-22 05:55PM
04:02PM
Oct-27-22 07:00AM
Oct-24-22 05:30AM
Oct-21-22 07:48AM
07:00AM
Oct-19-22 07:10AM
Oct-12-22 07:00AM
Sep-21-22 07:00AM
Sep-07-22 07:00AM
Aug-30-22 09:35AM
Aug-11-22 07:45AM
06:30AM
Aug-01-22 07:00AM
Jul-28-22 04:15PM
Jul-25-22 06:30AM
Jun-20-22 09:22AM
May-31-22 07:00AM
May-12-22 07:45AM
06:30AM
May-05-22 07:00AM
May-03-22 07:00AM
Apr-12-22 02:51PM
Apr-11-22 11:52AM
07:00AM
Apr-06-22 07:00AM
Mar-22-22 07:00AM
Mar-16-22 10:00AM
Mar-08-22 06:30AM
Feb-28-22 07:00AM
Jan-25-22 06:30AM
Jan-18-22 07:00AM
Dec-16-21 06:30AM
Dec-06-21 06:30AM
Nov-18-21 07:00AM
Nov-08-21 07:55AM
06:35AM
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.